share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Hickey Benjamin

施貴寶 | 4：持股變動聲明-高管 Hickey Benjamin

SEC announcement ·  03/05 07:02
牛牛AI助理已提取核心訊息
Bristol-Myers Squibb (BMY) has reported a transaction involving Benjamin Hickey, the President of RayzeBio Org., according to a recent filing. The transaction took place on March 1, 2024. However, the filing did not disclose specific details regarding the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Hickey after the transaction was not provided. This lack of detail in the report leaves investors without key information that could influence their investment decisions in Bristol-Myers Squibb stock.
Bristol-Myers Squibb (BMY) has reported a transaction involving Benjamin Hickey, the President of RayzeBio Org., according to a recent filing. The transaction took place on March 1, 2024. However, the filing did not disclose specific details regarding the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Hickey after the transaction was not provided. This lack of detail in the report leaves investors without key information that could influence their investment decisions in Bristol-Myers Squibb stock.
根據最近的一份文件，百時美施貴寶（BMY）報告了一筆涉及RayzeBio Org. 總裁本傑明·希基的交易。該交易於 2024 年 3 月 1 日進行。但是，該文件沒有透露有關交易的股票數量、股票性質、交易價格或股票總價值的具體細節。此外，沒有提供交易後Hickey持有的股票數量。報告缺乏細節，使投資者無法獲得可能影響他們對百時美施貴寶股票的投資決策的關鍵信息。
根據最近的一份文件，百時美施貴寶（BMY）報告了一筆涉及RayzeBio Org. 總裁本傑明·希基的交易。該交易於 2024 年 3 月 1 日進行。但是，該文件沒有透露有關交易的股票數量、股票性質、交易價格或股票總價值的具體細節。此外，沒有提供交易後Hickey持有的股票數量。報告缺乏細節，使投資者無法獲得可能影響他們對百時美施貴寶股票的投資決策的關鍵信息。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。